Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Bactiguard, Audiocast, Q2'26

By Inderes7/14/2026, 9:00 AM
Bactiguard

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christine Lind
00:00 - 07:39

Thank you, operator, and a warm welcome to everyone joining us for Bactiguard's second quarter presentation for 2026. I'm joined today by our CFO, Patrick Bach. And I'll take you through the quarter's strategic highlights, and then hand over to Patrick for a closer look at the numbers before we open the line up for your questions. Today's title, "Solid performance driven by revenue growth," captures exactly where we landed this quarter. Strong top-line momentum across the business, confirming that the slower start to the year was simply a matter of timing rather than any change in trend. So let's dive straight into the quarter and start with the numbers. We're pleased to report second quarter net sales growth, excluding currency, of 16%. The main driver was a recovery in BD revenues alongside one of the strongest quarters our Wound Management portfolio has ever recorded. This quarter confirms that the softer start to the year was a matter of timing, not a change in trend, as I said, and our strategy execution is on track. Adjusted EBITDA came in at 5.6 MSEK, up from 4.4 MSEK a year ago, lifted by sales growth and continued cost discipline. It's a good illustration of how top-line growth flows through to earnings in a scalable, license-based business, and it gives us room to keep investing in future growth. Cash flow from operations amounted to 12.4 MSEK, a clear step up from the 1.7 MSEK in the same quarter last year. Strategically, it was an eventful quarter. Second, we signed a new long-term agreement that deepens our already 35-year partnership with BD. We are seeing growth in the number of patients using Bactiguard-coated implants with Zimmer Biomet, and we had strong momentum in our early partner dialogues. Let me take you through these one at a time. Let's turn to BD. In May, we announced a new long-term agreement with BD, deepening a partnership that goes back to 1990, more than 35 years. Few things illustrate the long-term value that our coating technology creates for partners better than this, or how embedded Bactiguard-coated products become in patient care. Once adopted, what started as a collaboration covering select markets has steadily grown into a true global partnership. Today, it spans the full value chain from technology development to global market execution and is focused on expanding adoption of our infection prevention technology. The restated agreement modernizes the partnership terms and strengthens that foundation further. It builds on the December 2023 extension under which BD was granted worldwide exclusivity for Bactiguard-coated Foley catheters outside of China. Alongside the commercial terms, a key part of the agreement has been aligning on the regulatory approvals needed to support smooth market transitions, something that's been a shared focus with BD over the past two years, and that has now enabled recent launches in the Nordics, Poland, and parts of the Middle East. We have backed each of these commercialization initiatives with technology training across the regions, and we continue to transition our KOL relationships and former customers to support market access and commercial execution for BD. As I said when we announced the agreement back in May, this is a great example of the power and potential of our license-focused strategy, a partnership that's globally growing and built on shared success. In the quarter, BD revenues came in 50% above the weak second quarter of last year and are also up 8% so far this year, reaching 28.2 MSEK on a reported basis, as in prior quarters. BD revenues are shaped by the timing of concentrate shipments into their supply chain, which can create variation from one quarter to the next. But we continue to see underlying growth both from existing and new markets. Now to Zimmer Biomet, our partnership continues to focus on driving commercial adoption. Bactiguard is leading the work to transition the trauma implants to the MDR regulatory requirements in Europe and supporting the post-market clinical studies. We are very pleased to note that the first of the ongoing multicenter studies is now complete, which is an encouraging step, and the key comparative study is progressing according to plan. We are especially pleased to see growing use of Bactiguard-coated implants in patients. There is still meaningful headroom here, given how small a share of the total trauma market coated implants represent today. Overall, we see the partnership as financially stable, with revenues of 3.8 MSEK in the quarter in line with our expectations, double-digit growth in product sales and clear long-term potential as adoption continues to build. Let's turn to business development. We spent a good part of the quarter on new business development, meeting potential future partners at conferences and in direct discussions across the US and Europe. Since launching our five focused therapeutic areas back in March of 2025, we have now completed a full annual calendar of conferences across all of them where we focus on business development activities. The need to find infection prevention solutions is especially recognized in orthopedics, and it is clear that the strongest engagement with Bactiguard is here. We are also able to capitalize on this category by having rights in various orthopedic segments available for licensing. Since amending our agreement with Zimmer Biomet at the end of 2025, we remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements. We remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements. Now to Wound Management, which had a standout quarter; the portfolio delivered very strong performance indeed, with 67% revenue growth for the quarter and 25% over the first six months. Our flagship Hydrocyn aqua line led the way, supported by stabilization in sutures, with growth in the portfolio across the Middle East, Europe, and Asia. Tender business in select regions also gave a positive boost in the quarter. Alongside the strong commercial execution, we continue to strengthen the product portfolio, invest in the availability of products in new markets and build out our operational setup in Malaysia. As we've said before, we continue to expect double-digit growth from the combined Wound Management portfolio, fueled by high double-digit growth from Hydrocyn aqua and a stable contribution from sutures. And this quarter confirms that we continue to be on track with that. Over to Patrick for a closer look at the numbers.

Patrick Bach
07:41 - 11:57

Thank you. Thank you, Christine. We are very happy to present solid growth for Q2. We report both revenue growth, continued profitability, increased cash generation, and we see positive momentum across the business. Total revenue came in at 57 MSEK, up from 52 MSEK. Total revenues grew 12%. Net sales grew 16%, excluding currency effects. I said this is driven by strong growth in BD revenues and a very strong quarter from our Wound Management portfolio. In fact, this was the strongest quarter and the strongest revenues on a rolling 12-month basis ever. Looking closer at our core license business, we see license revenues lifted by the strong growth in BD, which came at 28.2 MSEK. This is up 50% versus a weak second quarter last year, but up 8% versus the first half of last year. And as said, we see strong continued underlying momentum in the BD business and the BD partnership. Zimmer Biomet contributed with approximately 4 MSEK in the quarter, in line with our expectations and reflecting historical trends. A double-digit growth in the sales of the Zimmer Biomet Bactiguard-coated nails. The reason for the decline in the total license revenues is found in the high comparable base from last year, in which Q2 included a full year of minimum royalties from the previous agreement. As communicated, fixed fees in our new agreement will be consistent across the quarters going forward. Across both partnerships, we continue to see positive in-market volume growth, and we are excited to see the future demand from customers and clinicians for our technology, which underpins and adds to the risk reduction efforts healthcare professionals must deal with on a daily basis. On OPEX, we remained cost-conscious and maintained cost discipline during the quarter, while also investing selectively to support growth. This includes, for example, our regulatory capabilities, business development activities, as well as strengthening our teams and operations globally, including in our Malaysian business. For the quarter, we did see an increase of total OPEX of 11%, while the half-year period holds about a 1.5% total increase in OPEX. The Q2 increase mainly pertains to timing effects on bonus accruals, which were reversed in Q1 2026 versus Q2 last year in 2025, i.e. A lower comparable for Q2. As communicated previously, we will continue to operate with cost discipline while ensuring the right investments in growth. On Adj. EBITDA, we came in close to 6 MSEK for the quarter, up from 4.4 MSEK in Q2 last year, driven by sales growth. And as I said, continued cost discipline. Our margin on adjusted EBITDA increased to 10% for the quarter, as well as approximately 10% for the first six-month period. Net profit for the quarter was -8.2 MSEK, in line with the -8.1 MSEK in Q2 last year. On cash flow, we see cash flow from operating activities amounted to a bit more than 12 MSEK for the quarter, a substantial improvement of more than 10 MSEK versus the 1.7 MSEK in Q2 last year. Also, total cash flow for the period was positive at 7.4 MSEK, and our total cash and cash equivalents at the quarter end amounted to 43.5 MSEK, up from approximately 35 MSEK at the end of Q1. So with that, back to you, Christine.

Christine Lind
12:02 - 13:35

Thank you. Patrick. With growth across all of our businesses, including double-digit increase in Wound Management, our focus now is on converting these investments into sustained traction. We are on the right track and we will keep executing towards our strategic targets. I want to be clear that nothing about the previous quarter changes our strategic direction or the fundamentals of the business. Our targets for 2030 stand unchanged. We remain focused on strengthening our partnerships, continuing to invest in our key knowledge areas that help advance our partners through regulatory approvals and to commercialization and building long-term value through disciplined execution across the portfolio. To sum up, this was a quarter of broad-based growth with net sales up 16% and further improvements in both Adj. EBITDA and cash flow. We renewed and deepened our 35-year partnership with BD, and we continue to see growing momentum with Zimmer Biomet, with double-digit growth in product sales as coated implant use in patients builds; Wound Management delivered one of the strongest quarters ever, up 67%. And we have a strong partnership pipeline building, particularly in orthopedics. Taken together, we remain firmly on track with that. Let's open up for questions.

Operator
13:37 - 13:55

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Maria Karlsson from DNB Carnegie. Please go ahead.

Maria Karlsson
13:58 - 14:24

Hi, Christine and Patrick. Are you there from Carnegie? Thanks for taking my questions. Great. So congratulations on that as well. I have some questions. However, on the COGS level. Historically, we have seen some lumpy gross profits and we see COGS increasing this quarter. How should we think about the gross margin profile going forward? I mean this is mostly a portfolio effect, but still, what should we expect going forward?

Patrick Bach
14:27 - 15:11

Yeah. Thank you, Maria, for your question. You are absolutely right. We have historically seen a somewhat lumpy COGS profile. We obviously try to have it less lumpy going forward. I think what we see in Q2 is not the same picture you will see going forward. Part of what drives the Q2 is product mix. We saw a higher volume of sales in Wound Management, obviously with the high growth in that segment. And we have also had some additional scrapping in Q2. So going forward, I think you can assume the level that we have seen consistently in the past periods.

Maria Karlsson
15:14 - 15:29

All right. Thank you. And talking about Wound Management, is this high growth repeatable? I mean you mentioned high double-digit growth there. And you also mentioned a positive boost from the tender business. Is there any proportion that you can talk to us about?

Patrick Bach
15:31 - 16:54

I think, in short, we would love if we continue to report 50% to 60% growth for Wound Management. But that, I think, is certainly not our expectation for the business. As we have said before, we have a confident long-term view on the business to deliver sustained double-digit growth that includes both the Hydrocyn aqua part of the business and the sutures business combined. As we have said before, we see the sutures business more as a stable business. Whereas in our portfolio, we see continued high double-digit growth, which we expect going forward. I think with this quarter, we have continuous confirmation that we see positive demand by customers, obviously from our distributors, of the portfolio. And as we have said, we have seen a stabilization of the sutures business this year, which affected us a bit last year. So we have a continued positive view on the growth coming from our Malaysian-based Wound Management business. As we've talked about before, we see growth across the regions, notably from the Middle Eastern region, from Europe, as well as our legacy markets in Asia.

Maria Karlsson
16:57 - 17:19

All right. And just a little more focus on costs. The MDR spend. Have you guided previously on what you expect the total MDR expenses to be? What should we expect in the second half of the year and maybe some timelines? How long are you planning to carry out the work with the MDR? Carry on the work with the MDR?

Patrick Bach
17:20 - 18:41

Yeah. I appreciate the question. I think in short, we have not provided guidance regarding that for the full year. We have an increased amount of non-recurring costs this year that we can single out that relate to MDR. This is what we highlight in the report. We have highlighted in the adjusted EBITDA the impact related to MDR costs. We have highlighted that we see this potential in 2026 and 2027. I believe that we will see more cost and the majority of the cost in 2026 versus 2027. We are halfway through the year, but we don't have specific guidance on the total costs; however, we will obviously continue to incur MDR-related costs that we consider non-recurring in the remaining Q3 and Q4 of this year. In addition to these regulatory costs, we have normal regulatory costs in our business, which we obviously do not single out. But we will continue to report these MDR-related non-recurring costs in the report for Q3 and Q4 as well.

Christine Lind
18:41 - 19:15

And Maria, this is Christine. From a qualitative standpoint, we can also comment that with BD, the underlying Foley product portfolio has already been upgraded to the MDR regulatory guidelines so that that product portfolio is complete from an MDR standpoint and is approved and is currently regulated under MDR, and we are currently working on both the transitions of the Zimmer Biomet trauma implants, as well as our wound management portfolio, all of which are, of course, device-related under the MDR regulations.

Maria Karlsson
19:18 - 19:24

All right. Thank you for the addition there. That was all my questions. Thank you very much. And yet again, congrats on the good quarter.

Unknown 1
19:25 - 19:26

Thank you. Thank you.

Operator
19:26 - 19:30

The next question comes from Matthias Madsen from CIB. Please go ahead.

Matthias Madsen
19:33 - 20:07

Hi. Thanks for taking my questions. I think it was good to see the revenues normalizing this quarter. Quite a good step up from Q1. I just want to ask if you would say this represents the sort of run rate you are at right now, with no specific items either helping or weighing it down. And if we are likely to see lower volatility in the revenue line going forward, or if the volatility will still be there based on your understanding.

Patrick Bach
20:09 - 22:07

Yes. Thank you, Matthias, for your question. We are of course also very happy to be able to report numbers that I think sustain what we have communicated as a very solid and positively underlying growing partnership and momentum for BD. What we have stated, and obviously what we've talked about in the past quarters, is that we did see an effect of some of the delayed registrations in Europe. We believe, and we of course work as much as we can to ensure that there will be less volatility going forward. So that is what we expect. That is what we hope. That is what we focus on. Matthias. What you see in Q2 for this quarter is obviously more similar to Q3 and Q4 of the last year, which were, as we also reported, more normal quarters. So I believe, yes, in short, this is about the level that we are very happy to see from BD and from there on, of course, we still continue and expect to grow. We do expect less volatility going forward, but of course, it is sometimes out of our hands, and we are not able to guide fully on this; however, as we said before, we see continued positive underlying growth in the BD business with mid-single-digit volume growth in the markets. And as Christine also communicated, we see a positive response from many new geographies, already preparing to have products available with Bactiguard-coated Foley catheters in these markets.

Matthias Madsen
22:10 - 22:24

I think that's a very clear answer. The next question relating to BD would be what share of the revenues there comes from new markets outside the US, Japan, etc. . Do you have that level of insights?

Patrick Bach
22:28 - 22:41

Thanks for your question, Matthias. Just to understand, what share of revenue is in the new markets that they will potentially or have launched in versus the existing markets?

Matthias Madsen
22:42 - 22:50

Yes, such as India and Europe, which were added to the agreement you had before.

Patrick Bach
22:52 - 24:18

I mean, in short, we do not have the split on these markets. And I think in fact, which is what obviously we and BD are trying to do together, is not to necessarily capture market share from existing other coated catheters. This rarely exists, but we aim to build the markets. We know today that obviously the existing markets, with the US being the biggest, have the biggest potential. So of course, we're trying to build a lot of additional markets that in size will not obviously be bigger than the existing business and it will take time, but this is the work that we are committed to and that BD is committed to. We see very positive response from these markets that have not had Bactiguard-coated Foley catheters available before. We see positive response from their sales teams, as they would like to offer this to their customers and to the patients ultimately. So we believe that the additional markets that we have now under the new global agreement will definitely sustain positive growth for BD going forward. But obviously, for the foreseeable future, it will still be a lesser portion of the total revenue base versus the existing markets.

Matthias Madsen
24:21 - 24:24

Thank you very much. Those were the questions I had today.

Patrick Bach
24:26 - 24:27

Thank you, Matthias.

Operator
24:27 - 24:34

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Christine Lind
24:39 - 24:55

Thank you. Operator. Thank you for all your questions and for your continued interest in Bactiguard. We appreciate the dialogue and look forward to updating you at our next available opportunity. And with that, back to you, operator, for closing out the call.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…